Serological Science for COVID-19 SeroNet

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-0-759102400011-23

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2024
    2025
  • Known Financial Commitments (USD)

    $180,000
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    lynn briscoe
  • Research Location

    United States of America
  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

In light of the emergence of the novel coronavirus, SARS-CoV-2, and the urgent need to mitigate the pathogen's spread. There is a crucial need for accurate laboratory-based methods for initial diagnosis, asymptomatic carriage and overall public health understanding of the extent of this disease. The current lack of validated and widely available standardized tests, procedures and reagents for assessment of SARS-CoV-2-specific antibody responses is a critical gap in the rapid response to the SARS-CoV-2 pandemic. a major goal and focus of SeroNet is determining the molecular and cellular components of the immune response to SARS-CoV-2 to understand the innate, humoral and adaptive response, as well as to understand barriers to access